Historical Control Analysis Demonstrates Greater Long‐Term Reduction in Plasma Globotriaosylceramide (Gb3) by Venglustat Compared With Placebo or Agalsidase Beta in Male Patients With Classic Fabry Disease
Molecular Genetics & Genomic Medicine · 2025
DOI: 10.1002/mgg3.70152 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Molecular Genetics & Genomic Medicine, 2025. Verfasst von Dominique P Germain und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Genetics, University of Versailles, Montigny, France. Hauptthemen laut MEDLINE: Fabry Disease, Trihexosylceramides, alpha-Galactosidase. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi.
Abstract (Originalsprache)
Purpose
To evaluate the disease biomarker response of venglustat in patients with Fabry disease (FD), utilizing data from a single‐arm phase 2 study of venglustat and a placebo‐controlled phase 3 study of agalsidase beta through historical control and case‐matched analyses.
Methods
Eleven venglustat‐treated male patients with classic FD in the phase 2 study were matched with placebo‐ or agalsidase beta–treated patients from the phase 3 study based on propensity scores at baseline. Changes from baseline in plasma globotriaosylceramide (GL‐3 or Gb3) concentrations were analyzed at approximately 6–36 months.
Results
Venglustat treatment resulted in greater significant reductions in plasma GL‐3 concentrations at 6 months from baseline vs. placebo (mean difference −2.56 μg/mL, p < 0.001), and at 24 and 36 months from baseline vs. agalsidase beta (mean difference −1.8 μg/mL, p < 0.05 and −2.35 μg/mL, p < 0.01, respectively). GL‐3 concentrations continued to decline with venglustat for up to 3 years without plateauing.
Conclusions
Venglustat showed significantly greater reductions in plasma GL‐3 concentrations than placebo after 6 months and agalsidase beta after 24 and 36 months. These findings support the potential of long‐term venglustat treatment to reduce GL‐3 accumulation in patients with classic FD. Further studies are needed to confirm clinical benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Genetics, University of Versailles, Montigny, France.
- French Referral Center for Fabry Disease and Lysosomal Diseases, MetabERN, AP-HP Paris-Saclay University, Garches, France.
- Sanofi, Cambridge, Massachusetts, USA.
- Lysosomal Disorders Unit, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
- Research Institute-Fundacion Jimenez Diaz, Autónoma University (IIS-FJD UAM), Madrid, Spain.
- Division of Medical Genetics, Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA.
ORCID-Profile: Dominique P Germain
Förderung
- Sanofi
Zitieren
APA
Germain, D. P., DasMahapatra, P., Liu, S., Deegan, P., Ortiz, A., Modur, V., & Wilcox, W. R. (2025). Historical Control Analysis Demonstrates Greater Long‐Term Reduction in Plasma Globotriaosylceramide (Gb3) by Venglustat Compared With Placebo or Agalsidase Beta in Male Patients With Classic Fabry Disease. Molecular Genetics & Genomic Medicine. https://doi.org/10.1002/mgg3.70152
Vancouver
Germain DP, DasMahapatra P, Liu S, Deegan P, Ortiz A, Modur V, et al. Historical Control Analysis Demonstrates Greater Long‐Term Reduction in Plasma Globotriaosylceramide (Gb3) by Venglustat Compared With Placebo or Agalsidase Beta in Male Patients With Classic Fabry Disease. Molecular Genetics & Genomic Medicine. 2025. doi:10.1002/mgg3.70152
BibTeX
@article{Germain2025,
author = {Germain, Dominique P and DasMahapatra, Pronabesh and Liu, Shiguang and Deegan, Patrick and Ortiz, Alberto and Modur, Vijay and Wilcox, William R},
title = {Historical Control Analysis Demonstrates Greater Long‐Term Reduction in Plasma Globotriaosylceramide (Gb3) by Venglustat Compared With Placebo or Agalsidase Beta in Male Patients With Classic Fabry Disease},
journal = {Molecular Genetics & Genomic Medicine},
year = {2025},
doi = {10.1002/mgg3.70152}
}
EUVIMED